Background The incidence of epilepsy is high within the first few years of life, stabilizes over
the second through fifth decades, and then rises again. Treatment of elderly patients with …

Introduction Clinical practice studies help guide antiepileptic drug (AED) therapy in patient
groups routinely excluded from clinical trials, such as the elderly. The Euro-Esli study …

Purpose Eslicarbazepine-acetate (ESL) is a third generation antiepileptic drug licensed as
adjunctive therapy in adults with focal seizures. Efficacy and safety of ESL have been …

Objective To investigate the safety and tolerability of eslicarbazepine acetate (ESL), a once-
daily oral anti-seizure drug (ASD), in older and younger adult patient populations. Methods …

Introduction The prevalence of epilepsy increases in elderly patients aged> 65 years, and
treatment is challenging because clinical data are limited. Objective Our objective was to …

Objective To assess the effectiveness and tolerability of eslicarbazepine acetate (ESL)
monotherapy in routine clinical practice for the treatment of focal‐onset seizures. Methods …

Purpose Eslicarbazepine acetate (ESL) is indicated for treatment of focal epilepsy. Our aim
was to evaluate the effect and tolerability of ESL in elderly and younger adults. The primary …

Abstract Background Eslicarbazepine acetate (ESL, Aptiom®) is a once-daily (QD)
anticonvulsant, approved as adjunctive treatment of partial-onset seizures (POS). It is …

Abstract The Euro-Esli study was an exploratory pooled analysis of data from 14 European
clinical practice studies, which was conducted to audit the real-world effectiveness, safety …

Introduction We report outcomes from an open-label, non-randomized, 24-week study of
eslicarbazepine acetate (ESL) in adults at earlier and later stages of their treatment history …